Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Go back to Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Regeneron (NASDAQ: REGN) Delayed: 806.51 -0.97 (0.12%)
Previous Close $807.48    52 Week High $592.36 
Open $806.74    52 Week Low $325.35 
Day High $813.86    P/E 211.68 
Day Low $800.24    EPS $3.81 
Volume 338,564